In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Turning Around Medtronic Vascular

Executive Summary

Scott Ward, head of Medtronic Vascular, talks about rebuilding this business with, without and beyond drug-eluting stents, while being third in a blockbuster market.

Related Content

Leaving Medtronic: Bill Hawkins' Legacy
B. Braun's Bet on Balloons
COURAGE Trial: Bad News Again for Stents at ACC, Or Is It?
Business & Technology Briefs (03/2007)
Carotid Stenting: Trials and Tribulations
Industry Perspective - The Medtech Industry: A Look Back at 2006
TCT Highlights: Late Stent Thrombosis Controversy Continues
Renewed DES Safety Debate Creates Second Generation Mover Advantage
Medtronic Scoops Up PercuSurge
Medtronic Strikes Again, This Time With AVE


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts